How Research Sites Win More Trials: The Real Selection Formula
Every Research Director knows the frustration. You and your clinical operations team spend 35 hours meticulously completing a 50-page Feasibility Questionnaire (FQ) for a high-value Phase II oncology protocol. You pull Electronic Health Record (EHR) counts, audit past investigator performance, confirm ultra-cold chain storage capacity, and map your clinical research coordinators' (CRC) bandwidth.
Three weeks later, you receive a sterile, automated rejection email. Worse, the trial is awarded to a competing site across town—a site you know lacks your therapeutic depth.
Here is the reality pharmaceutical sponsors and Global CROs rarely disclose: traditional site selection rubrics are largely performative.
Industry benchmarks from the Tufts Center for the Study of Drug Development (CSDD) reveal that 11% of selected investigative sites never enroll a single subject , and an astonishing 37% fail to meet their minimum accrual targets . Sponsors know this. Because historical feasibility data is notoriously inaccurate, sponsor selection committees discount the estimates sites provide by as much as 50% to 60%.
When sponsors evaluate your site, they are not grading the optimism of your questionnaire responses. They run your site through predictive risk algorithms designed to penalize unverified data.
To break this cycle, Research Directors must stop treating trial feasibility as a clerical exercise and start approaching it as a strategic, data-driven partnership. Here is how modern trial sponsors actually make selection decisions—and how the TheraNovex TrialMatch Platform helps elite research sites position themselves as unavoidable choices for protocol allocation.
The Hidden Playbook: Why Traditional Feasibility Fails Research Directors
The fundamental flaw in traditional site selection lies in the reliance on static, retrospective data.
When a sponsor releases a Request for Information (RFI), they typically ask: "How many patients with this indication did you treat in the last 12 months?" A research director pulls billing codes (ICD-10) and reports 450 patients.
However, sponsor feasibility algorithms immediately apply standard attrition heuristics: -40% for strict biomarker exclusions (e.g., HER2-negative, specific KRAS mutations) -30% for line-of-therapy restrictions -25% for protocol visit burden and geographic radius friction -20% for competing trials already running at your site
Your pool of 450 quickly plummets to fewer than 10 actual candidates. When your site fails to meet accrual projections, your site performance profile suffers inside internal sponsor databases, hurting your pipeline for future awards.
Traditional Site Selection vs. Algorithmic Matching ┌─────────────────────────────────┐ ┌─────────────────────────────────┐ │ Traditional Feasibility │ │ TheraNovex TrialMatch Model │ ├─────────────────────────────────┤ ├─────────────────────────────────┤ │ • Static ICD-10 Record Counts │ vs │ • Phenotypically Verified Pools │ │ • 40+ Page Manual Questionnaires│ │ • Dynamic Protocol Matching │ │ • Unverified Capacity Promises │ │ • Validated Patient Velocity │ │ • 50-60% Sponsor Discount Rate │ │ • Algorithmic Site Verification │ └─────────────────────────────────┘ └─────────────────────────────────┘
Winning trials requires replacing rough assumptions with verified, recruit-ready prospective cohorts. True sponsor collaboration occurs when you prove feasibility using the exact criteria their clinical program managers use to de-risk their studies.
4 Ways Research Directors Can Modernize Site Feasibility
1. Shift from Crude EHR Querying to Deep Phenotypic Validation Broad diagnostic codes no longer win competitive studies. Sponsors want assurance that your prospective subject base matches nuanced inclusion/exclusion (I/E) criteria.
Instead of reporting raw volume, high-performing sites conduct granular phenotypic screening prior to submitting feasibility assessments: Cross-referencing primary diagnoses against concurrent lab values (e.g., eGFR levels, platelet thresholds, liver function markers) Auditing prior lines of therapy to identify wash-out viability Assessing social determinants of health (SDOH) that impact retention
How TheraNovex Powers This: The TheraNovex TrialMatch Platform connects directly to distributed clinical registries and real-world data (RWD) environments. It parses complex multi-variable protocols against live patient profiles in minutes, eliminating manual chart checks. When submitting your feasibility data through TheraNovex, you present sponsors with pre-screened, I/E-modeled patient cohorts, building immediate trust with selection executives.
2. Quantify Recruitment Velocity Instead of Gross Patient Volume Gross volume is a vanity metric; recruitment velocity is what keeps studies on budget. A study by the Tufts CSDD indicates that study delays cost sponsors between $600,000 and $8 million each day an asset is stalled in development.
Selection directors do not simply ask: "Does this site have 20 patients?" They ask: "Can this site enroll 2 patients per month consistently without protocol deviations?"
To win site selection, present a defensible timeline: First Patient In (FPI) Timeline: Realistic screening-to-randomization runways. Coordinator Bandwidth Ratio: Calculated patient-to-CRC capacity. Screen Failure Buffer: Demonstrated conversion rates for past trials in the same indication.
Sites deploying data-backed recruitment models through TheraNovex consistently demonstrate a 42% reduction in cycle time from protocol delivery to First Patient In (FPI) . Demonstrating this operational rigor directly inside your feasibility submission removes sponsor uncertainty.
Sponsor Selection Matrix Scoring ┌──────────────────────────────┬───────────────────┬───────────────────┐ │ Evaluation Category │ Standard Site │ TheraNovex Site │ ├──────────────────────────────┼───────────────────┼───────────────────┤ │ Cohort Accuracy │ 35-45% (Estimated)│ 94% (Pre-screened)│ │ Time to Complete Feasibility │ 14-21 Business Days│ < 48 Hours │ │ Enrollment Predictability │ High Variance │ Verified Velocity │ │ Strategic Alignment Score │ Low / Unrated │ Preferred Partner │ └──────────────────────────────┴───────────────────┴───────────────────┘
3. Replace Static Questionnaires with Dynamic Feasibility Assets Filling out redundant Word documents and web portals is a resource sink. Research sites spend up to 18% of their administrative work hours on non-reimbursed feasibility questionnaires.
Sponsors evaluate dozens of near-identical submissions. Sites stand out when they present interactive, verifiable profiles: A real-time audit of active site capacity and competing trial footprints Geo-spatial heatmaps of diverse community patient populations within 30 miles Historic audit data demonstrating zero regulatory findings on prior audits
The TheraNovex TrialMatch platform centralizes your site's physical infrastructure, patient population demographics, and investigator metrics into a living asset. When a sponsor searches the TrialMatch network, your site profile matches their protocol criteria instantly—cutting feasibility processing time from weeks to hours.
4. Build Direct, Strategic Sponsor Collaboration Many sites wait reactively for RFIs to arrive from CRO vendor networks. By the time an RFI hits your inbox, the CRO has often already selected their primary and backup sites; your questionnaire serves merely as insurance or benchmarking fodder.
To break out of the "backup site" trap, progressive Research Directors practice proactive pipeline engagement: Identifying Phase I/II readouts that will progress into Phase III studies over the next 6–12 months Engaging medical science liaisons (MSLs) with targeted, pre-screened patient demographics long before an RFP goes out Operating within trusted sponsor technology ecosystems rather than fragmented email chains
TheraNovex alters this dynamic by embedding your research site directly into the sponsor’s trial planning phase. Instead of competing in cold RFIs, your site is dynamically recommended by our predictive algorithms while the sponsor designs the study protocol.
How the TheraNovex TrialMatch Platform Secures Your Trial Pipeline
TheraNovex was built to solve the broken information asymmetry between clinical sites and pharmaceutical sponsors. Research Directors do not need more administrative questionnaires; they need an automated mechanism to demonstrate capability and win competitive allocations.
HOW THERANOVEX TRIALMATCH PLATFORM WORKS ┌────────────────────────────────────────────────────────┐ │ TheraNovex TrialMatch Engine │ └───────────────────────────┬────────────────────────────┘ │ ┌───────────────────────┴───────────────────────┐ ▼ ▼ ┌───────────────────────────────┐ ┌───────────────────────────────┐ │ RESEARCH DIRECTORS │ │ PHARMA SPONSORS & CROs │ ├───────────────────────────────┤ ├───────────────────────────────┤ │ • Automated cohort matching │ │ • Protocol feasibility audit │ │ • Real-time velocity metrics │ ◄───► │ • Direct site discovery │ │ • Decreased admin burden │ │ • Verified recruitment data │ │ • Higher protocol allocation │ │ • Accelerated FPI timelines │ └───────────────────────────────┘ └───────────────────────────────┘
The TheraNovex TrialMatch Platform provides:
1. Predictive Cohort Validation: Our platform aggregates de-identified clinical records across primary and specialty touchpoints, evaluating deep I/E criteria against complex study flags. When you commit to enrolling 15 subjects, you do so with a 94% enrollment accuracy rate , backed by real patient matches. 2. Instant Feasibility Architecture: Stop rebuilding questionnaires from scratch. TrialMatch continuously synchronizes your site's operational equipment, staffing bandwidth, and past compliance history. When protocols surface, your feasibility assessment compiles rapidly, reducing submission turnaround time by up to 65% . 3. Preferred Placement in Sponsor Networks: Global sponsors use TheraNovex to build their site lists based on algorithmically verified recruitment capacity. Instead of fighting for attention, your site receives high-priority, inbound protocol opportunities tailored to your real clinical strengths.
Stop Guessing. Start Dominating Site Feasibility.
The site selection model has shifted. Sponsors no longer reward unverified claims or boilerplate survey answers. They deploy computational scrutiny to evaluate site reliability, recruitment velocity, and protocol feasibility.
Sites that rely on yesterday's EHR queries will continue to see dwindling study allocations and delayed trials. Those that use algorithmically verified data will secure higher study volume, build direct sponsor partnerships, and spend less time on administration.
Your patient pool is your site's most valuable asset. Isn't it time you proved it?
Learn how TheraNovex helps research directors achieve this and modernize their trial recruitment pipeline.
